HEPA
Hepion Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.09
+33.33%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.4x
Market Cap
$1.02M
MomentumView details →
1D Return
+33.33%
YTD Return
+15.83%
RSI (14)
51.0
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.4x
Market Cap
$1.02M
RSI (14)
51.0
MomentumView details →
1D Return
+33.33%
YTD Return
+15.83%
SummaryUpdated Jun 1, 2026
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) is a clinical-stage biopharmaceutical company founded in 2013 and headquartered in Edison, New Jersey. Originally incorporated as ContraVir Pharmaceuticals, the company rebranded to Hepion Pharmaceuticals in July 2019 to better reflect its focus on liver disease therapeutics. The company went public in February 2014 and has since dedicated its efforts to developing innovative drug therapies for chronic liver diseases, with its lead candidate Rencofilstat currently in clinical development for treating non-alcoholic steatohepatitis (NASH) and other liver conditions.
Similar companies
Latest newsMore news →
Hepion Pharmaceuticals entered into securities purchase agreements to sell 8,000,000 shares of common stock and warrants for 8,000,000 shares at $0.05 per share, raising gross proceeds of $400,000.9d agoJames Liddy was appointed as a director of Hepion Pharmaceuticals, Inc., effective August 19, 2026.16d ago